ClinicalTrials.gg
CompletedNCT00744757Updated Sep 9, 2013Results posted

An Efficacy and Safety Study of Decitabine in Participants With Myelodysplastic Syndrome (MDS)

A Phase 2 interventional study of Decitabine in Myelodysplastic Syndrome, sponsored by Johnson & Johnson Taiwan Ltd. Completed at 6 sites in Taiwan. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2013-09-09.

Sponsored by Johnson & Johnson Taiwan Ltd (part of Johnson & Johnson) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
37
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 75 studies testing decitabine in Myelodysplastic Syndromes — 9 open to participants now, 16 under way, 1 of them phase 3. Decitabine · Myelodysplastic Syndromes.

Enrollment
41st of 74
37 · median 43
Started
2008
with 5 others
Phase 2
36 of 75
5 open now
Registered
18th of 75
by date

Among the 75 studies testing decitabine in Myelodysplastic Syndromes, this one is the 41st largest by enrollment of the 74 interventional ones that give a count, is one of 6 that started in 2008, is one of 36 in phase 2, and was the 18th registered.

Myelodysplastic Syndromes

1,997 studies on the registry are indexed under Myelodysplastic Syndromes; 324 are open to participants now.

Browse Myelodysplastic Syndromes studies →

Open to participants now

9 of the 75 studies testing decitabine in Myelodysplastic Syndromes are open now, in 3 countries. Recruiting first, the newest first:

4 more — sign in →

By country, each count listing its studies:

All 9 open studies →

About decitabine

Decitabine: first FDA approval 2006 (DACOGEN), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 264 Myelodysplastic Syndromes studies recruiting now, 167 (63%) set no upper age limit and 70 (27%) stop at 75 or younger; 57 take children under 18; 17 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 75 studies testing decitabine in Myelodysplastic Syndromes, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the response rate of decitabine in previously treated and untreated Taiwanese participants with Myelodysplastic Syndrome (MDS - a disease associated with decreased production of blood cells, blood cells are produced but do not mature normally).

Read the detailed description

This is an open-label (a medical research study in which participants and researchers are told which treatments the participants are receiving, "unblinded"), multi-center (when more than 1 hospital or medical school team work on a medical research study), single-arm study of decitabine. The study will consist of 5 phases: Pre-treatment phase (before 30 days of first dose), Treatment phase (consist of 8 cycles, each cycle of 28 days), End-of-treatment phase (consist of 30-42 days after the last dose of cycle 8, or at time of discontinuation), Extension phase (1 cycle of 4 weeks) and Post-study phase or follow-up phase (every 2 months until 1 year, lost to follow-up or death). Participants who achieve a complete remission (when a medical problem gets better or goes away at least for a while) will be treated for at least 2 more cycles after first documentation of complete response (CR), after which treatment can be discontinued. Decitabine in a dose of 20 milligram per square meter (mg per m\^2) will be administered intravenously over 1 hour infusion, 1 hour, once daily for 5 consecutive days of a 28 days cycle up to 8 cycles or continued until disease progression or unacceptable toxicity. The primary objective is to evaluate the best response rate (complete response and partial response). Participants' safety will be monitored throughout the study.

03

Conditions studied

  • Myelodysplastic Syndrome

Keywords

  • 5-aza-2'-deoxycytidine
  • decitabine
  • dacogen
  • Myelodysplastic Syndrome
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants with documented pathological (bone marrow, no longer than 30 days before first dosing in study) evidence of Myelodysplastic syndromes (MDS) or of chronic myelomonocytic leukemia (CMML) by World health organisation classification
  • Participants with international prognostic scoring system (IPSS) score equal to 0.5 or more (only for participants for whom IPSS is applicable)
  • Participants with an Eastern oncology cooperative group () performance status of 0-2
  • Participants with adequate hepatic (liver) and renal (kidney) function as measured by pre-treatment laboratory criteria within 21 days of starting treatment with decitabine
  • Participants must have recovered from toxic effects of previous therapy and not receiving any chemotherapy for a minimum of 4 weeks (6 weeks if the participants has been treated with a nitrosoureas) before to the first dose of study drug

Exclusion criteria

Exclusion Criteria:

  • Participants with a diagnosis of acute myeloid leukemia (AML) (greater than 30 percent bone marrow blasts)
  • Participants with AML with multilineage dysplasia (abnormal development or cell growth) following MDS (20-30 percent bone marrow blasts) can be enrolled. For these latter participants an observation period of 1 month is necessary to exclude those participants with rapid progression to full blown AML
  • Participants with previous treatment with azacitadine or decitabine or hematopoietic stem cell transplantation less than 1 year prior to study enrollment
  • Participants with past history of and received any treatment for this before malignancy within the last 3 years, except for superficial bladder cancer, basal cell or squamous cell carcinoma of the skin, cervical intraepithelial neoplasia (CIN) or prostate intraepithelial neoplasia (PIN)
  • Participants with known (surface antigen-positive) or active infection
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
37 participants (actual)

Study arms

  • Experimental
    Decitabine

    Decitabine 20 milligram per square meter (mg per m\^2) will be administered intravenous (into a vein) infusion (a fluid or a medicine delivered into a vein by way of a needle) over 1 hour, once daily for 5 consecutive days of a 28 days cycle up to 8 cycles or continued until disease progression or unacceptable toxicity.

    Drug: Decitabine

Interventions

  • Decitabine 20 mg per m\^2 will be administered intravenous infusion over 1 hour, once daily for 5 consecutive days of a 28 days cycle up to 8 cycles or continued until disease progression or unacceptable toxicity.

    Also known as: Dacogen, 5-aza-2'-deoxycytidine

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Response

    Percentage of participants with response: complete response (CR) or partial response (PR) according to International Working Group (IWG) 2006 criteria was evaluated. CR in bone marrow is defined as\<=to 5% myeloblasts with normal maturation of all cell lines and persistent dysplasia was noted in peripheral blood hemoglobin \>=11 gram (g) per deciliter (dl), platelets \>=100\*10\^9 liter (l), neutrophils \>=1.0\*10\^9 l, Blasts 0%. Partial response is defined as all CR criteria if abnormal before treatment except: bone marrow blasts decreased by \>=50% over pre-treatment but still \>=5%.

    Time frame: Day 1 of Cycle 2, 4, 6, 8; each Cycle of 28 days and End of treatment (30-42 days after Cycle 8 or early withdrawal)

Secondary outcomes

  1. Percentage of Participants With Hematologic Treatment Response

    Hematologic treatment response was assessed as per IWG 2006 criteria. This is measured in erythroid(HI-E), platelet(HI-P) and neutrophil(HI-N) lineages. HI-E response(pre-treatment\<11 gram per deciliter \[g/dl\]):hemoglobin increase by\>=1.5 g/dl and relevant reduction in RBC transfusions by 4 RBC transfusions/8week. HI-P response (pre-treatment\<100\*109/l):absolute increase of \>=30\*10\^9/l for participants starting with\>20\*10\^9/l and increase from \<20\*10\^9/l to\>20\*10\^9/l and by at least 100%. HI-N response (pre-treatment\<1.0\*10\^9/l): at least 100% increase and an absolute increase \>0.5\*10\^9/l.

    Time frame: Day 1 of Cycle 1, 2, 3, 4, 5, 6, 7 and 8, each Cycle of 28 days and End of treatment (30-42 days after Cycle 8 or early withdrawal)

  2. Percentage of Participants With Cytogenetic Response

    Cytogenetic responses was assessed as per IWG 2006 criteria which define complete response as disappearance of the chromosomal abnormality without appearance of new ones and partial response as at least 50 percent reduction of the chromosomal abnormality.

    Time frame: Day 1 of Cycle 2, 4, 6, 8; each Cycle of 28 days and End of treatment (30-42 days after Cycle 8 or early withdrawal)

  3. Time to Acute Myeloid Leukemia (AML) Progression or Death

    Time to AML is defined as greater than 30 percent of blasts in bone marrow or the time to death was calculated from the date of treatment start until disease progression to AML or until death, which ever occurred first. Participants who were still alive and did not progress to AML were censored at the moment of last visit.

    Time frame: Start of treatment until disease progression or death (whichever occur first) or up to 736 days

  4. Overall Survival

    Overall survival was defined as the time from the date of treatment start until death (whatever the cause). It was calculated from Kaplan-Meier estimates. Participants still alive were censored at the moment of last visit or contact.

    Time frame: Start of treatment until disease progression or death (whichever occur first) or up to 736 days

  5. Percentage of Participants With Transfusion Dependency

    Transfusion requirements for both red blood cells as well as platelets were recorded for each participant.

    Time frame: 8 weeks before first dose until disease progression or death (whichever occur first) or up to 736 days

  6. Percentage of Participants With Transfusion Independency

    Transfusion independent participants were calculated from all the participants who required transfusion in the duration of 8 weeks before first dose until disease progression or death or up to 736 days. Transfusion independence was defined as lack of requirement for transfusions for at least 8 weeks.

    Time frame: 8 weeks before first dose and 736 days of treatment

  7. Duration for Hospitalization

    Duration of hospitalization was calculated for each participant, using the sum of all hospital days by subtracting the date of discharge from the date of admission.

    Time frame: Cycle 1 up to Cycle 8, each cycle of 28 days.

  8. Number of Events Which Led to Hospitalization

    The events (reasons) for hospitalizations such as infection, transfusion, acute choleycystitis, allergic transfusion reaction, dyspnoea with right pleural effusion, febrile neutropenia, fever, for decitabine, Myelodysplastic Syndrome (MDS) hematuria, paronychia, pneumonia, heart failure, peri-anal abscess (PAA), pancytopenia,fluctuated neutropenia fever, right dorsal foot cellulitis, Right lower (Rt.Lw) lung pneumonia with impending respiratory (resp) failure, Serious adverse event (SAE)+schedule hospitalization for decitabine, septic shock and not available were reported.

    Time frame: Start of treatment until disease progression or death or up to Cycle 8, each cycle of 28 days

  9. Quality of Life Assessment

    The quality of life was assessed by the questionnaire QLQ C-30 designed by European Organization for the Research and Treatment of Cancer (EORTC). EORTC QLQ-C30 is a 30-item questionnaire to assess the overall quality of life in cancer participants. Most questions used 4-point scale (1=Not at All' to 4=Very Much') and 2 questions: Q29 on overall health and Q30 on overall quality of life uses 7-point scale ranging from 1=Very Poor to 7=Excellent. Higher score indicates better quality of life.

    Time frame: Day 1 of Cycle 1 and Cycle 8 (each cycle of 28 days)

07

Results

Posted Aug 15, 2013

Participant flow

Participant flow — Overall Study
MilestoneDecitabine
Started37
Completed16
Not completed21
Withdrew: Objective disease progression7
Withdrew: Physician decision5
Withdrew: Withdrawal by subject1
Withdrew: Death6
Withdrew: Adverse event2

Outcome measures

PrimaryPercentage of Participants With Response

Percentage of participants with response: complete response (CR) or partial response (PR) according to International Working Group (IWG) 2006 criteria was evaluated. CR in bone marrow is defined as\<=to 5% myeloblasts with normal maturation of all cell lines and persistent dysplasia was noted in peripheral blood hemoglobin \>=11 gram (g) per deciliter (dl), platelets \>=100\*10\^9 liter (l), neutrophils \>=1.0\*10\^9 l, Blasts 0%. Partial response is defined as all CR criteria if abnormal before treatment except: bone marrow blasts decreased by \>=50% over pre-treatment but still \>=5%.

Time frame:
Day 1 of Cycle 2, 4, 6, 8; each Cycle of 28 days and End of treatment (30-42 days after Cycle 8 or early withdrawal)
Reported as:
Number · Percentage of Participants
Percentage of Participants With Response
Percentage of ParticipantsDecitabine
Percentage of Participants With Response23.5
SecondaryPercentage of Participants With Hematologic Treatment Response

Hematologic treatment response was assessed as per IWG 2006 criteria. This is measured in erythroid(HI-E), platelet(HI-P) and neutrophil(HI-N) lineages. HI-E response(pre-treatment\<11 gram per deciliter \[g/dl\]):hemoglobin increase by\>=1.5 g/dl and relevant reduction in RBC transfusions by 4 RBC transfusions/8week. HI-P response (pre-treatment\<100\*109/l):absolute increase of \>=30\*10\^9/l for participants starting with\>20\*10\^9/l and increase from \<20\*10\^9/l to\>20\*10\^9/l and by at least 100%. HI-N response (pre-treatment\<1.0\*10\^9/l): at least 100% increase and an absolute increase \>0.5\*10\^9/l.

Time frame:
Day 1 of Cycle 1, 2, 3, 4, 5, 6, 7 and 8, each Cycle of 28 days and End of treatment (30-42 days after Cycle 8 or early withdrawal)
Reported as:
Number · Percentage of participants
Percentage of Participants With Hematologic Treatment Response
Percentage of participantsDecitabine
Cycle 1: HI-E5.9
Cycle 1: HI-P8.8
Cycle 1: HI-N2.9
Cycle 2: HI-E17.2
Cycle 2: HI-P27.6
Cycle 2: HI-N6.9
Cycle 3: HI-E28.6
Cycle 3: HI-P39.3
Cycle 3: HI-N17.9
Cycle 4: HI-E37.0
Cycle 4: HI-P33.3
Cycle 4: HI-N7.4
Cycle 5: HI-E40.9
Cycle 5: HI-P40.9
Cycle 5: HI-N13.6
Cycle 6: HI-E52.4
Cycle 6: HI-P61.9
Cycle 6: HI-N19.1
Cycle 7: HI-E47.1
Cycle 7: HI-P52.9
Cycle 7: HI-N5.9
Cycle 8: HI-E43.8
Cycle 8: HI-P56.3
Cycle 8: HI-N12.5
End of treatment: HI-E27.6
End of treatment: HI-P34.5
End of treatment: HI-N6.9
SecondaryPercentage of Participants With Cytogenetic Response

Cytogenetic responses was assessed as per IWG 2006 criteria which define complete response as disappearance of the chromosomal abnormality without appearance of new ones and partial response as at least 50 percent reduction of the chromosomal abnormality.

Time frame:
Day 1 of Cycle 2, 4, 6, 8; each Cycle of 28 days and End of treatment (30-42 days after Cycle 8 or early withdrawal)
Reported as:
Number · Percentage of participants
Percentage of Participants With Cytogenetic Response
Percentage of participantsDecitabine
Cycle 2, Complete Response (n=18)22.2
Cycle 2, Partial Response (n=18)0.0
Cycle 4, Complete Response (n=20)20.0
Cycle 4, Partial Response (n=20)25.0
Cycle 6, Complete Response (n=11)18.2
Cycle 6, Partial Response (n=11)27.3
Cycle 8, Complete Response (n=6)0.0
Cycle 8, Partial Response (n=6)0.0
End of treatment, Complete Response (n=17)11.8
End of treatment, Partial Response (n=17)5.9
SecondaryTime to Acute Myeloid Leukemia (AML) Progression or Death

Time to AML is defined as greater than 30 percent of blasts in bone marrow or the time to death was calculated from the date of treatment start until disease progression to AML or until death, which ever occurred first. Participants who were still alive and did not progress to AML were censored at the moment of last visit.

Time frame:
Start of treatment until disease progression or death (whichever occur first) or up to 736 days
Reported as:
Median · Months
Time to Acute Myeloid Leukemia (AML) Progression or Death
MonthsDecitabine
Time to Acute Myeloid Leukemia (AML) Progression or Death22.8 (0.3 to 25.4)
SecondaryOverall Survival

Overall survival was defined as the time from the date of treatment start until death (whatever the cause). It was calculated from Kaplan-Meier estimates. Participants still alive were censored at the moment of last visit or contact.

Time frame:
Start of treatment until disease progression or death (whichever occur first) or up to 736 days
Reported as:
Median · Months
Overall Survival
MonthsDecitabine
Overall Survival22.8 (0.3 to 25.4)
SecondaryPercentage of Participants With Transfusion Dependency

Transfusion requirements for both red blood cells as well as platelets were recorded for each participant.

Time frame:
8 weeks before first dose until disease progression or death (whichever occur first) or up to 736 days
Reported as:
Number · Percentage of participants
Percentage of Participants With Transfusion Dependency
Percentage of participantsDecitabine
Percentage of Participants With Transfusion Dependency100
SecondaryPercentage of Participants With Transfusion Independency

Transfusion independent participants were calculated from all the participants who required transfusion in the duration of 8 weeks before first dose until disease progression or death or up to 736 days. Transfusion independence was defined as lack of requirement for transfusions for at least 8 weeks.

Time frame:
8 weeks before first dose and 736 days of treatment
Reported as:
Number · percentage of participants
Percentage of Participants With Transfusion Independency
percentage of participantsDecitabine
Percentage of Participants With Transfusion Independency27
SecondaryDuration for Hospitalization

Duration of hospitalization was calculated for each participant, using the sum of all hospital days by subtracting the date of discharge from the date of admission.

Time frame:
Cycle 1 up to Cycle 8, each cycle of 28 days.
Reported as:
Mean · Days
Duration for Hospitalization
DaysDecitabine
Cycle 1 (n=37)9.0 ± 9.4
Cycle 2 (n=30)15.4 ± 16.2
Cycle 3 (n=28)13.3 ± 11.5
Cycle 4 (n=28)27.1 ± 52.9
Cycle 5 (n=22)22.5 ± 38.6
Cycle 6 (n=21)7.5 ± 5.0
Cycle 7 (n=17)33.3 ± 56.5
Cycle 8 (n=16)5.0 ± 0.0
SecondaryNumber of Events Which Led to Hospitalization

The events (reasons) for hospitalizations such as infection, transfusion, acute choleycystitis, allergic transfusion reaction, dyspnoea with right pleural effusion, febrile neutropenia, fever, for decitabine, Myelodysplastic Syndrome (MDS) hematuria, paronychia, pneumonia, heart failure, peri-anal abscess (PAA), pancytopenia,fluctuated neutropenia fever, right dorsal foot cellulitis, Right lower (Rt.Lw) lung pneumonia with impending respiratory (resp) failure, Serious adverse event (SAE)+schedule hospitalization for decitabine, septic shock and not available were reported.

Time frame:
Start of treatment until disease progression or death or up to Cycle 8, each cycle of 28 days
Reported as:
Number · Events
Number of Events Which Led to Hospitalization
EventsDecitabine
Infection10
Transfusion4
Acute choleycystitis1
Allergic transfusion reaction1
Dyspnoea with right pleural effusion4
Febrile neutropenia16
Fever4
For Decitabine33
MDS hematuria2
Paronychia, pneumonia, heart failure1
PAA,pancytopenia,fluctuated neutropenia fever1
Right dorsal foot cellulitis1
Rt Lw lung pneumonia with impending resp. failure1
SAE+Schedule hospitalization for Decitabine4
Septic shock1
Not available36
SecondaryQuality of Life Assessment

The quality of life was assessed by the questionnaire QLQ C-30 designed by European Organization for the Research and Treatment of Cancer (EORTC). EORTC QLQ-C30 is a 30-item questionnaire to assess the overall quality of life in cancer participants. Most questions used 4-point scale (1=Not at All' to 4=Very Much') and 2 questions: Q29 on overall health and Q30 on overall quality of life uses 7-point scale ranging from 1=Very Poor to 7=Excellent. Higher score indicates better quality of life.

Time frame:
Day 1 of Cycle 1 and Cycle 8 (each cycle of 28 days)
Reported as:
Mean · Unit on a scale
Quality of Life Assessment
Unit on a scaleDecitabine
Baseline, Q294.4 ± 1.5
Baseline, Q304.9 ± 1.3
End of treatment, Q294.3 ± 1.7
End of treatment, Q304.5 ± 1.8

Adverse events

Collected over Baseline up to 30 days after last medication. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Decitabine—28/37 (75.7%)37/37 (100%)
Most frequent serious events
Showing 10 of 55
Most frequent serious events
EventDecitabine
Febrile neutropeniaBlood and lymphatic system disorders19/37
PneumoniaInfections and infestations7/37
PyrexiaGeneral disorders5/37
Septic shockInfections and infestations4/37
AnaemiaBlood and lymphatic system disorders3/37
PancytopeniaBlood and lymphatic system disorders3/37
Multi-organ failureGeneral disorders3/37
Acute respiratory failureRespiratory, thoracic and mediastinal disorders3/37
NeutropeniaBlood and lymphatic system disorders2/37
ThrombocytopeniaBlood and lymphatic system disorders2/37
Most frequent other events
Showing 10 of 137
Most frequent other events
EventDecitabine
LeucopeniaBlood and lymphatic system disorders28/37
AnaemiaBlood and lymphatic system disorders23/37
NeutropeniaBlood and lymphatic system disorders22/37
ThrombocytopeniaBlood and lymphatic system disorders20/37
NauseaGastrointestinal disorders14/37
Decreased appetiteMetabolism and nutrition disorders14/37
DizzinessNervous system disorders14/37
CoughRespiratory, thoracic and mediastinal disorders14/37
PyrexiaGeneral disorders13/37
FatigueGeneral disorders13/37

Baseline characteristics

Age Continuous
Age Continuous(Years)Decitabine
Mean68.0 ± 14.1
Sex: Female, Male
Sex: Female, Male(Participants)Decitabine
Female11
Male26
08

Study locations

6 sites
  • Changhua, Taiwan
  • Kaohsiung, Taiwan
  • Taichung, Taiwan
  • Tainan, Taiwan
  • Taipei, Taiwan
  • Tau-Yuan County 333, Taiwan
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 2008, a primary completion of Sep 2010 and a completion of Aug 2012. It does not say whether these dates are actual or estimated.

Results were first posted in Aug 2013, 2 years 11 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 29, 2008
First posted
Sep 1, 2008
Start
Aug 2008
Primary completionActual
Sep 2010
CompletionActual
Aug 2012
Results first posted
Aug 15, 2013
Last update
Sep 9, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 9, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00744757
Responsible party
Sponsor
First posted
Sep 1, 2008
Start date
Aug 2008
Primary completion
Sep 2010
Completion
Aug 2012
Results posted
Aug 15, 2013
Last update
Sep 9, 2013

Study contacts

Johnson & Johnson Taiwan, Ltd. Clinical Trial
study director · Johnson & Johnson Taiwan Ltd

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Decitabine

Start the discussion